Azitra Inc AZTR

$0.53 -0.04 (-6.82%)

Valuation

Market cap
3,685,000
Revenue TTM
$0
Net income TTM
$-10,960,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
126,017
Avg volume
3,310,506
Day's range
$0.52 – $0.60
Shares out
6,060,000
Stochastic %K
5%
Beta
-0.90
Analysts
Strong Buy
Price target
$3.50

Price

Company profile

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epid...

Show more

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.

Industry
Biotechnology
Sector
Healthcare
Phone
203 646 6446
Website
https://azitrainc.com
Address
21 Business Park Drive, Branford, United States

Latest news

No headlines yet.